TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8561059
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplement (15g) + 100 mg alpha-tocopheryl acetate
Study: 8561059
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplement (15g) + 200 mg alpha-tocopheryl acetate
Study: 8561059
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplement (15g) + 400 mg alpha-tocopheryl acetate
Study: 8561059
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplement (15g)
Study: 8561059
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplement (15g) + alpha-tocopheryl acetate
Study: 29680222
Drug: Vocal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vocal therapy associated with electromyographic biofeedback
Study: 29680222
Drug: Traditional vocal
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional vocal therapy (Placebo Group)
Study: 25003264
Drug: 12.5% maltodextrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5% maltodextrin plus 15 g of glutamine (glutamine group)
Study: 11443472
Drug: Preincisional ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preincisional ketamine 1 mg/kg IV and local infiltration with 20 ml ropivacaine (10 mg/ml)
Study: 11443472
Drug: Preincisional saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preincisional saline IV and local infiltration with 20 ml ropivacaine (10 mg/ml)
Study: 8032178
Drug: Commercially used
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercially used antiglaucoma agents with nasolacrimal occlusion
Study: 31784300
Drug: Teduglutide treatment
Normalized name: Teduglutide
DrugBank: Teduglutide (DB08900)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Teduglutide treatment for 24 weeks
Study: 18833170
Drug: Movalis injected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Movalis injected into trigger points (3 injections + 15 mg tablets per day)
Study: 18833170
Drug: Movalis intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Movalis intramuscular injection (3 injections + 15 mg tablets per day)
Study: 11049005
Drug: Intravenous diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diclofenac (25 mg)
Study: 11049005
Drug: Intravenous diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diclofenac (50 mg)
Study: 11049005
Drug: Intravenous diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diclofenac (all doses)
Study: 9093544
Drug: High energy
Normalized name: High energy formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: High energy breakfast (over 20% of recommended daily energy intake)
Study: 9093544
Drug: Low energy
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low energy breakfast (less than 10% of recommended daily energy intake)
Study: 2943752
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate (CPA) 50 mg/day orally for 3 months
Study: 2943752
Drug: Depot preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depot preparation of LHRH superagonist (DTrp6‐LHRH) 3 mg intramuscularly approximately once a month for 3 months
Study: 29608680
Drug: Extended infusion
Normalized name: Extended Infusion Set 6mm Cannula 23" Tubing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended infusion of β-lactams (4 hours)
Study: 29608680
Drug: Bolus infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bolus infusion of β-lactams (30 minutes)
Study: 27394386
Drug: Weight management
Normalized name: Estroven Weight Management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight management counseling by telephone before and during pregnancy, with weekly contacts during the first 6 months and monthly contacts for the next 18 months. Unlimited access to a study website providing self-management tools.
Study: 24259553
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g eicosapentaenoic acid (EPA) + 1 g docosahexaenoic acid
Study: 15705012
Drug: Control (drug-free)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (drug-free) for 4 weeks
Study: 12742483
Drug: Tacrolimus (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus (target level 12 to 15 ng/mL in the first month)
Study: 12742483
Drug: Sirolimus (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus (target level 12 to 18 ng/mL in the first month)
Study: 8671965
Drug: ANP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ANP infusion (0.005 microg/kg*min; group II, n=15)
Study: 1834065
Drug: Nicorandil 4
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil 4 mg i.v.
Study: 1834065
Drug: Glyceryl trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glyceryl trinitrate (GTN) 0.3 mg i.v.
Study: 26482574
Drug: Person-centered physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Person-centered physical therapy
Study: 25133491
Drug: Topical tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical tranexamic acid (TXA) 5% and phenylephrine 0.5%
Study: 18177775
Drug: Parenteral ampicillin
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parenteral ampicillin (100 mg/kg per day in four doses for 48 hours, followed by 3 days of oral amoxicillin (80-90 mg/kg per day); n=1012
Study: 18177775
Drug: Home-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based treatment with oral amoxicillin (80-90 mg/kg per day in two doses for 5 days; n=1025
Study: 15797885
Drug: Naltrexone plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone plus psychotherapy treatment
Study: 15797885
Drug: Psychotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapy treatment alone
Study: 11026862
Drug: Bladder volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bladder volume of 100 ml
Study: 11026862
Drug: Bladder volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bladder volume of 70 ml
Study: 11026862
Drug: Bladder volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bladder volume of 35 ml
Study: 1618997
Drug: Pyridostigmine (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine (120 mg oral)
Study: 4038550
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of promethazine and chlorpromazine rectal suppositories
Study: 28082368
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of conservative therapies including education for joint protection and OA, a splint for the base of the thumb, hand exercises, and topical diclofenac sodium 1% gel over 6 weeks.
Study: 28082368
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of conservative therapies (Intervention group).
Study: 17552374
Drug: Gaboxadol 5
Normalized name: Gaboxadol
DrugBank: Gaboxadol (DB06554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gaboxadol 5 mg (GBX5)
Study: 17552374
Drug: Gaboxadol 10
Normalized name: Gaboxadol
DrugBank: Gaboxadol (DB06554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gaboxadol 10 mg (GBX10)
Study: 17552374
Drug: Gaboxadol 15
Normalized name: Gaboxadol
DrugBank: Gaboxadol (DB06554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gaboxadol 15 mg (GBX15)
Study: 17552374
Drug: Zolpidem 10
Normalized name: zolpidem 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 10 mg (ZOL10)
Study: 11130129
Drug: TIVA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIVA with propofol (4 mg/kg/h) and remifentanil (0.25 microgram/kg/min)
Study: 11130129
Drug: TIVA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIVA with propofol (4 mg/kg/h) and sufentanil (1 microgram/kg)
Study: 9175664
Drug: Closure of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closure of subcutaneous fat tissue
Study: 9175664
Drug: No closure
Approvals — FDA: no, EMA: no, PMDA: no
Description: No closure of subcutaneous fat tissue
Study: 1606772
Drug: Cyclophosphamide for
Normalized name: Cyclophosphamide for Injection
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide for 6 months, warfarin and dipyridamole for two years
Study: 23733767
Drug: Schedule A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule A: decitabine 20 mg/m² SC per day for 3 consecutive days on days 1, 2, and 3 every 28 days
Study: 23733767
Drug: Schedule B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule B: decitabine 20 mg/m² SC per day once every 7 days on days 1, 8, and 15 every 28 days
Study: 18925510
Drug: Transfusion volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfusion volume of 10 ml/kg
Study: 18925510
Drug: Transfusion volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfusion volume of 15 ml/kg
Study: 8843534
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg of melatonin
Study: 8843534
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg of melatonin
Study: 10781447
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream (5 g per chest tube cutaneously 3 h before CTR)
Study: 10781447
Drug: IV morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV morphine (0.1 mg/kg up to 10 mg IV 30 min before CTR)
Study: 1430301
Drug: Morning dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning dose of 200 mg valproic acid (VPA) after a light meal
Study: 1430301
Drug: Evening dose
Normalized name: Jornay PM, (evening dose) 60 mg/24 hr oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening dose of 200 mg valproic acid (VPA) after a heavy meal
Study: 1430301
Drug: Evening dose
Normalized name: Jornay PM, (evening dose) 60 mg/24 hr oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening dose of 200 mg valproic acid (VPA) after a light meal
Study: 3005756
Drug: Short‐acting steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short‐acting steroid (fluocortolone or prednisone) on three out of four days
Study: 3005756
Drug: Daily steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily steroid treatment (15 mg prednisone or more per day)
Study: 24656872
Drug: Consumption of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consumption of fruits (80 g) and vegetables (60 g)
Study: 19962289
Drug: Preventive treatment
Normalized name: STANNOUS FLUORIDE 0.004 g in 1 g DENTAL GEL [Enamelon Preventive Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive treatment (diet)
Study: 18661258
Drug: Protein (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein (15 g of whey both before and after exercise)
Study: 10784465
Drug: Nortriptyline (25-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline (25-100 mg/day)
Study: 12568180
Drug: Erythromycin 250
Normalized name: erythromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 250 mg i.v. every 8 hours
Study: 29439668
Drug: Adjuvant HIPEC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant HIPEC with Mitomycin C (60 min at 42-43 °C) followed by routine adjuvant systemic chemotherapy
Study: 29439668
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (systemic chemotherapy only)
Study: 25114132
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g PAS twice daily
Study: 25114132
Drug: 8 g
Normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 g PAS once daily
Study: 25114132
Drug: Concurrent efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent efavirenz (EFV) medication
Study: 20470675
Drug: 532 nm
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 532 nm laser therapy with retinaldehyde-based topical application
Study: 20470675
Drug: 532 nm
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 532 nm laser therapy alone
Study: 15897496
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy alone (control)
Study: 12552351
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of [(123)I]IPT
Study: 12552351
Drug: Drug-naive children
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-naive children with ADHD
Study: 7317246
Drug: Oral atropine
Normalized name: atropine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral atropine 30 microgram kg‐1 90 min before operation
Study: 30442329
Drug: Integrated cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated cognitive behavioral therapy (ICART)
Study: 27513344
Drug: Topical Pidobenzone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Pidobenzone 4% combined with fractional CO2 laser or cryotherapy
Study: 21972847
Drug: 0.12% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% chlorhexidine (daily immersion for 20 minutes after dinner)
Study: 21972847
Drug: Control (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (daily overnight soaking in water)
Study: 20200041
Drug: Imatinib, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib, 400 mg orally once daily for 1 year
Study: 18567762
Drug: Liquid vitamin
Normalized name: Liquid Vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid vitamin D supplement with food (DS+)
Study: 18567762
Drug: Liquid vitamin
Normalized name: Liquid Vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid vitamin D supplement without food (DS‐)
Study: 16084849
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 mg daily) with Indinavir (800 mg) and Ritonavir (100 mg)
Study: 16084849
Drug: Diltiazem (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (120 mg daily) with Indinavir (800 mg) and Ritonavir (100 mg)
Study: 8958015
Drug: Turbo fast
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turbo fast low angle shot MRI during drug‐induced sleep
Study: 1415200
Drug: Enisoprost (EP)
Normalized name: acetaminophen
DrugBank: Enisoprost (DB19319)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enisoprost (EP) 100 micrograms orally four times daily for 2 weeks
Study: 26746456
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of exercise and diet
Study: 24823465
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (COM) with MET 1000 mg twice a day and roflumilast 500 μg every day
Study: 24823465
Drug: Metformin (MET)
Normalized name: metformin / pioglitazone Oral Tablet [Actoplus Met]
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (MET) 1000 mg twice a day
Study: 24823465
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (COM)
Study: 24823465
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment interventions
Study: 12722398
Drug: New agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: New agents introduced into therapy
Study: 8116037
Drug: PTX 800
Normalized name: PTX-100
DrugBank: PTX-100 (DB18125)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTX 800 mg
Study: 2506913
Drug: Cromolyn sodium
Normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cromolyn sodium (Nalcrom) 200 mg orally, four times daily, starting 3 days before and continuing up to 3 days after food ingestion challenge.
Study: 1069551
Drug: Sustaining chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustaining chemotherapy alone
Study: 30021394
Drug: Nutraceutical compounds
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutraceutical compounds (NCs) containing red yeast rice and coenzyme Q10 added to diet for 2 months
Study: 27095389
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy plus ketamine
Study: 1978469
Drug: Both drugs
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drugs (Chlorpromazine and Remoxipride)
Study: 351804
Drug: Naloxone (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (specific dosage and duration not mentioned)
Study: 30203755
Drug: Ultrasonic atomized
Normalized name: Atomic Balm
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasonic atomized inhalation of antibiotics with targeted nursing
Study: 15459584
Drug: Fibrinolytic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinolytic agents (ASSENT-2 trial participants)
Study: 15459584
Drug: Fibrinolytic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinolytic agents (non-A2 patients at trial hospitals)
Study: 15459584
Drug: Fibrinolytic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinolytic agents (non-A2-Hosp patients)
Study: 12492612
Drug: Chloramphenicol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloramphenicol (25 mg kg‐1 6 hourly for 72 h) + Fosphenytoin (18 mg kg‐1)
Study: 12492612
Drug: Fosphenytoin (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosphenytoin (18 mg kg‐1) + Cefotaxime (25 mg kg‐1 8 hourly for 72 h)
Study: 776348
Drug: Intravenous vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vitamin K1 (2-5 mg)
Study: 25846209
Drug: rBet v
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rBet v 1 tablets (12.5-50 μg) administered once daily for 5 months
Study: 21827215
Drug: St John's
Normalized name: St john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: St John's Wort (SJW) 325 mg three times daily for 14 days
Study: 15251534
Drug: Ultra-low-dose pure
Normalized name: Dream Pure BB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low-dose pure follicle-stimulating hormone (FSH)
Study: 1622160
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg loracarbef
Study: 1622160
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg loracarbef
Study: 30690509
Drug: Anti-gp41 antibody
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-gp41 antibody levels
Study: 29601897
Drug: Topical capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical capsaicin and warmth
Study: 27548448
Drug: Intravitreal ocriplasmin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ocriplasmin 125 µg injection
Study: 18849193
Drug: Prednisolone (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (60 mg per day for 5 days, then reduced by 10 mg per day for a total of 10 days)
Study: 18849193
Drug: Valaciclovir (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valaciclovir (1000 mg three times per day for 7 days)
Study: 15914049
Drug: Durogesic fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Durogesic fentanyl transdermal reservoir (TDF)
Study: 15914049
Drug: Oral sustained-release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sustained-release morphine (SRM)
Study: 11106307
Drug: Citalopram (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (40 mg i.v.)
Study: 8657447
Drug: Zantac (histamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zantac (histamine H2-receptor antagonist)
Study: 1310921
Drug: Dobutamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine infusion at 10 micrograms min‐1 kg‐1
Study: 1310921
Drug: Dobutamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine infusion at 2 and 5 micrograms min‐1 kg‐1
Study: 30627737
Drug: midazolam 50 µg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: midazolam 50 µg/ml plus lidocaine 2% and hyaluronidase 15 IU/ml (Group M1)
Study: 30627737
Drug: midazolam 100 µg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: midazolam 100 µg/ml plus lidocaine 2% and hyaluronidase 15 IU/ml (Group M2)
Study: 30627737
Drug: lidocaine 2%
Normalized name: LIDOCAINE 2% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: lidocaine 2% and hyaluronidase 15 IU/ml (Group C)
Study: 24519039
Drug: peginterferon‐α2a and
Approvals — FDA: no, EMA: no, PMDA: no
Description: peginterferon‐α2a and 800 mg daily dose of ribavirin
Study: 15673895
Drug: 2-chloroprocaine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-chloroprocaine (40 mg)
Study: 15673895
Drug: bupivacaine (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine (7.5 mg)
Study: 8314652
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral doses of E2020 (0.3 mg, 1 mg, 2 mg, 5 mg, 8 mg, 10 mg) in fasting condition
Study: 8314652
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of E2020 (2 mg) after a meal
Study: 8314652
Drug: Repeated oral
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated oral doses of E2020 (2 mg once daily for 21 days)
Study: 8314652
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of E2020 (10 mg)